290 filings
ARS
2023 FY
AXSM
Axsome Therapeutics Inc
26 Apr 24
Annual report to shareholders
4:33pm
DEF 14A
AXSM
Axsome Therapeutics Inc
Definitive proxy
26 Apr 24
4:32pm
8-K
AXSM
Axsome Therapeutics Inc
1 Apr 24
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
8:27am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
9:06am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
9:02am
8-K
wpql gukf
19 Mar 24
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
7:06am
8-K
to4wi1j mb21b9l13tnn
20 Feb 24
Corporate Presentation February 2024
4:30pm
8-K
9w5el 2sw
20 Feb 24
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:05am
8-K
1tpa 5kdsx54v
8 Jan 24
Corporate Presentation January 2024
7:10am
8-K
l0wjamghmm6 aromfq
4 Jan 24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:11am
8-K
k83irzdm tpc
7 Dec 23
Other Events
4:05pm
8-K
me5ip4d3l4kf8idau72
6 Nov 23
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
ckidttz5
11 Oct 23
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
5:03pm
8-K
wy3wulk tk4hrx7n7
15 Aug 23
Corporate Presentation August 2023
7:45am
8-K
jxm9k
7 Aug 23
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
xjpoaz01ps1zgm88
4 Aug 23
Other Events
4:49pm
8-K
f40msmvs57sa76sti3
7 Jul 23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
8:21am